Tag: #Global Trends

Key Development Juvmo does not replace levodopa. But it gives AbbVie a new dopamine mechanism that can move the company... Read more

Key Development Oral GLP-1 therapy has moved beyond being a more convenient alternative to injections. It is becoming a commercially... Read more

Key Development  Roche and Ionis Pharmaceuticals have reported successful topline Phase 3 interim results for their investigational antisense oligonucleotide (ASO),... Read more

Key Development Two patients with the same BMI may not respond to GLP-1 therapy in the same way. New real-world... Read more

Key Development The 15.5% weight-loss figure is the obvious headline. The strategically more important number may be the 2.65-percentage-point reduction... Read more

Key Development Europe still has world-class universities, scientists, manufacturing capabilities and pharmaceutical companies. The problem is that more capital, clinical... Read more

Key Development A $6.5 billion API facility signals that Lilly no longer treats manufacturing as simply a downstream function supporting... Read more

Key Development There is still no FDA-approved therapy specifically designed to treat Sjögren's disease. A successful Phase 3 trial therefore... Read more

Key Development Less than two years from program launch to the clinic, compared with the roughly six-year industry benchmark cited... Read more